Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.92 USD | -0.58% | -4.36% | -45.32% |
25/04 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
25/04 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.32% | 722M | |
+7.65% | 111B | |
+11.23% | 106B | |
-12.33% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.60% | 16.81B | |
+38.60% | 12.54B | |
-24.25% | 8.09B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Goldman Sachs Adjusts Price Target on Sage Therapeutics to $25 From $22, Maintains Neutral Rating